Testosterone and estrogen in multiple sclerosis: from pathophysiology to therapeutics

References

• Compston A, Coles A. Multiple sclerosis. Lancet. 2008;372:1502–1517.
   PubMed Web of Science ®Google Scholar
• Baecher-Allan C, Kaskow BJ, Weiner HL. Multiple sclerosis: mechanisms and immunotherapy. Neuron. 2018;97:742–768.
   PubMed Web of Science ®Google Scholar
• Rolf L, Damoiseaux J, Hupperts R, et al. Network of nuclear receptor ligands in multiple sclerosis: common pathways and interactions of sex-steroids, corticosteroids and vitamin D3-derived molecules. Autoimmun Rev. 2016;15:900–910.
   PubMed Web of Science ®Google Scholar
• Jimenez-Balderas FJ, Tapia-Serrano R, Fonseca ME, et al. High frequency of association of rheumatic/autoimmune diseases and untreated male hypogonadism with severe testicular dysfunction. Arthritis Res. 2001;3:362–367.
   PubMedGoogle Scholar
• Noonan CW, Kathman SJ, White MC. Prevalence estimates for MS in the United States and evidence of an increasing trend for women. Neurology. 2002;58:136–138.
   PubMed Web of Science ®Google Scholar
• Orton SM, Herrera BM, Yee IM, et al. Sex ratio of multiple sclerosis in Canada: a longitudinal study. Lancet Neurol. 2006;5:932–936.
   PubMed Web of Science ®Google Scholar
• Schwendimann RN, Alekseeva N. Gender issues in multiple sclerosis. Int Rev Neurobiol. 2007;79:377–392.
   PubMed Web of Science ®Google Scholar
• Pakpoor J, Goldacre R, Schmierer K, et al. Testicular hypofunction and multiple sclerosis: cause or consequence? Reply. Ann Neurol. 2014;76:765–766.
   PubMed Web of Science ®Google Scholar
• Safarinejad MR. Evaluation of endocrine profile, hypothalamic-pituitary-testis axis and semen quality in multiple sclerosis. J Neuroendocrinol. 2008;20:1368–1375.
   PubMed Web of Science ®Google Scholar
• Wei T, Lightman SL. The neuroendocrine axis in patients with multiple sclerosis. Brain. 1997;120(Pt 6):1067–1076.
   PubMed Web of Science ®Google Scholar
• Tomassini V, Onesti E, Mainero C, et al. Sex hormones modulate brain damage in multiple sclerosis: MRI evidence. J Neurol Neurosurg Psychiatry. 2005;76:272–275.
   PubMed Web of Science ®Google Scholar
• Schumacher M, Hussain R, Gago N, et al. Progesterone synthesis in the nervous system: implications for myelination and myelin repair. Front Neurosci. 2012;6:10.
   PubMed Web of Science ®Google Scholar
• Spence RD, Voskuhl RR. Neuroprotective effects of estrogens and androgens in CNS inflammation and neurodegeneration. Front Neuroendocrinol. 2012;33:105–115.
   PubMed Web of Science ®Google Scholar
• Vukusic S, Hutchinson M, Hours M, et al. Pregnancy and multiple sclerosis (the PRIMS study): clinical predictors of post-partum relapse. Brain. 2004;127:1353–1360.
   PubMed Web of Science ®Google Scholar
• Confavreux C, Vukusic S, Adeleine P. Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain. 2003;126:770–782.
   PubMed Web of Science ®Google Scholar
• Cottrell DA, Kremenchutzky M, Rice GP, et al. The natural history of multiple sclerosis: a geographically based study. 5. The clinical features and natural history of primary progressive multiple sclerosis. Brain. 1999;122(Pt 4):625–639.
   PubMed Web of Science ®Google Scholar
• Hawkins SA, McDonnell GV. Benign multiple sclerosis? Clinical course, long term follow up, and assessment of prognostic factors. J Neurol Neurosurg Psychiatry. 1999;67:148–152.
   PubMed Web of Science ®Google Scholar
• Parmenter BA, Denney DR, Lynch SG, et al. Cognitive impairment in patients with multiple sclerosis: association with the APOE gene and promoter polymorphisms. Mult Scler. 2007;13:25–32.
   PubMedGoogle Scholar
• Savettieri G, Messina D, Andreoli V, et al. Gender-related effect of clinical and genetic variables on the cognitive impairment in multiple sclerosis. J Neurol. 2004;251:1208–1214.
   PubMed Web of Science ®Google Scholar
• Bove R, Musallam A, Healy BC, et al. Low testosterone is associated with disability in men with multiple sclerosis. Mult Scler. 2014;20:1584–1592.
   PubMed Web of Science ®Google Scholar
• Moore S, Patel R, Hannsun G, et al. Sex chromosome complement influences functional callosal myelination. Neuroscience. 2013;245:166–178.
   PubMed Web of Science ®Google Scholar
• Nieschlag E, Kumar N, Sitruk-Ware R. 7alpha-methyl-19-nortestosterone (MENTR): the population council’s contribution to research on male contraception and treatment of hypogonadism. Contraception. 2013;87:288–295.
   PubMed Web of Science ®Google Scholar
• Bebo BF Jr., Schuster JC, Vandenbark AA, et al. Gender differences in experimental autoimmune encephalomyelitis develop during the induction of the immune response to encephalitogenic peptides. J Neurosci Res. 1998;52:420–426.
   PubMed Web of Science ®Google Scholar
• Dalal M, Kim S, Voskuhl RR. Testosterone therapy ameliorates experimental autoimmune encephalomyelitis and induces a T helper 2 bias in the autoantigen-specific T lymphocyte response. J Immunol. 1997;159:3–6.
   PubMed Web of Science ®Google Scholar
• Liva SM, Voskuhl RR. Testosterone acts directly on CD4+ T lymphocytes to increase IL-10 production. J Immunol. 2001;167:2060–2067.
   PubMed Web of Science ®Google Scholar
• Spritzer MD, Galea LA. Testosterone and dihydrotestosterone, but not estradiol, enhance survival of new hippocampal neurons in adult male rats. Dev Neurobiol. 2007;67:1321–1333.
   PubMed Web of Science ®Google Scholar
• Lustig RH. Sex hormone modulation of neural development in vitro. Horm Behav. 1994;28:383–395.
   PubMed Web of Science ®Google Scholar
• Ogata T, Nakamura Y, Tsuji K, et al. Steroid hormones protect spinal cord neurons from glutamate toxicity. Neuroscience. 1993;55:445–449.
   PubMed Web of Science ®Google Scholar
• Chisu V, Manca P, Zedda M, et al. Effects of testosterone on differentiation and oxidative stress resistance in C1300 neuroblastoma cells. Neuro Endocrinol Lett. 2006;27:807–812.
   PubMed Web of Science ®Google Scholar
• Chisu V, Manca P, Lepore G, et al. Testosterone induces neuroprotection from oxidative stress. Effects on catalase activity and 3-nitro-L-tyrosine incorporation into alpha-tubulin in a mouse neuroblastoma cell line. Arch Ital Biol. 2006;144:63–73.
   PubMed Web of Science ®Google Scholar
• Ziehn MO, Avedisian AA, Dervin SM, et al. Therapeutic testosterone administration preserves excitatory synaptic transmission in the hippocampus during autoimmune demyelinating disease. J Neurosci. 2012;32:12312–12324.
   PubMed Web of Science ®Google Scholar
• Golden LC, Voskuhl R. The importance of studying sex differences in disease: the example of multiple sclerosis. J Neurosci Res. 2017;95:633–643.
   PubMed Web of Science ®Google Scholar
• Celotti F, Melcangi RC, Negri-Cesi P, et al. Testosterone metabolism in brain cells and membranes. J Steroid Biochem Mol Biol. 1991;40:673–678.
   PubMed Web of Science ®Google Scholar
• Patel R, Moore S, Crawford DK, et al. Attenuation of corpus callosum axon myelination and remyelination in the absence of circulating sex hormones. Brain Pathol. 2013;23:462–475.
   PubMed Web of Science ®Google Scholar
• Hussain R, Ghoumari AM, Bielecki B, et al. The neural androgen receptor: a therapeutic target for myelin repair in chronic demyelination. Brain. 2013;136:132–146.
   PubMed Web of Science ®Google Scholar
• Bielecki B, Mattern C, Ghoumari AM, et al. Unexpected central role of the androgen receptor in the spontaneous regeneration of myelin. Proc Natl Acad Sci U S A. 2016;113:14829–14834.
   PubMed Web of Science ®Google Scholar
• Sicotte NL, Giesser BS, Tandon V, et al. Testosterone treatment in multiple sclerosis: a pilot study. Arch Neurol. 2007;64:683–688.
   PubMed Web of Science ®Google Scholar
• Gold SM, Chalifoux S, Giesser BS, et al. Immune modulation and increased neurotrophic factor production in multiple sclerosis patients treated with testosterone. J Neuroinflammation. 2008;5:32.
   PubMed Web of Science ®Google Scholar
• Kurth F, Luders E, Sicotte NL, et al. Neuroprotective effects of testosterone treatment in men with multiple sclerosis. Neuroimage Clin. 2014;4:454–460.
   PubMed Web of Science ®Google Scholar
• Caruso D, D’Intino G, Giatti S, et al. Sex-dimorphic changes in neuroactive steroid levels after chronic experimental autoimmune encephalomyelitis. J Neurochem. 2010;114:921–932.
   PubMed Web of Science ®Google Scholar
• Giatti S, D’Intino G, Maschi O, et al. Acute experimental autoimmune encephalomyelitis induces sex dimorphic changes in neuroactive steroid levels. Neurochem Int. 2010;56:118–127.
   PubMed Web of Science ®Google Scholar
• Massella A, D’Intino G, Fernandez M, et al. Gender effect on neurodegeneration and myelin markers in an animal model for multiple sclerosis. BMC Neurosci. 2012;13:12.
   PubMed Web of Science ®Google Scholar
• Tiwari-Woodruff S, Morales LB, Lee R, et al. Differential neuroprotective and antiinflammatory effects of estrogen receptor (ER)alpha and ERbeta ligand treatment. Proc Natl Acad Sci U S A. 2007;104:14813–14818.
   PubMed Web of Science ®Google Scholar
• Kim RY, Mangu D, Hoffman AS, et al. Oestrogen receptor β ligand acts on CD11c± cells to mediate protection in experimental autoimmune encephalomyelitis. Brain. 2018;141:132–147.
   PubMed Web of Science ®Google Scholar
• Ziehn MO, Avedisian AA, Dervin SM, et al. Estriol preserves synaptic transmission in the hippocampus during autoimmune demyelinating disease. Lab Invest. 2012;92:1234–1245.
   PubMed Web of Science ®Google Scholar
• Lelu K, Delpy L, Robert V, et al. Endogenous estrogens, through estrogen receptor alpha, constrain autoimmune inflammation in female mice by limiting CD4+ T-cell homing into the CNS. Eur J Immunol. 2010;40:3489–3498.
   PubMed Web of Science ®Google Scholar
• Spence RD, Wisdom AJ, Cao Y, et al. Estrogen mediates neuroprotection and anti-inflammatory effects during EAE through ERalpha signaling on astrocytes but not through ERbeta signaling on astrocytes or neurons. J Neurosci. 2013;33:10924–10933.
   PubMed Web of Science ®Google Scholar
• Javadian A, Salehi E, Bidad K, et al. Effect of estrogen on Th1, Th2 and Th17 cytokines production by proteolipid protein and PHA activated peripheral blood mononuclear cells isolated from multiple sclerosis patients. Arch Med Res. 2014;45:177–182.
   PubMed Web of Science ®Google Scholar
• Luchetti S, van Eden CG, Schuurman K, et al. Gender differences in multiple sclerosis: induction of estrogen signaling in male and progesterone signaling in female lesions. J Neuropathol Exp Neurol. 2014;73:123–135.
   PubMed Web of Science ®Google Scholar
• Christianson MS, Mensah VA, Shen W. Multiple sclerosis at menopause: potential neuroprotective effects of estrogen. Maturitas. 2015;80:133–139.
   PubMed Web of Science ®Google Scholar
• McClain MA, Gatson NN, Powell ND, et al. Pregnancy suppresses experimental autoimmune encephalomyelitis through immunoregulatory cytokine production. J Immunol. 2007;179:8146–8152.
   PubMed Web of Science ®Google Scholar
• Sicotte NL, Liva SM, Klutch R, et al. Treatment of multiple sclerosis with the pregnancy hormone estriol. Ann Neurol. 2002;52:421–428.
   PubMed Web of Science ®Google Scholar
• Soldan SS, Alvarez Retuerto AI, Sicotte NL, et al. Immune modulation in multiple sclerosis patients treated with the pregnancy hormone estriol. J Immunol. 2003;171:6267–6274.
   PubMed Web of Science ®Google Scholar
• Voskuhl RR, Wang H, Wu TC, et al. Estriol combined with glatiramer acetate for women with relapsing-remitting multiple sclerosis: a randomised, placebo-controlled, phase 2 trial. Lancet Neurol. 2016;15:35–46.
   PubMed Web of Science ®Google Scholar
• Vukusic S, Ionescu I, El-Etr M, et al. The prevention of post-partum relapses with progestin and estradiol in multiple sclerosis (POPART’MUS) trial: rationale, objectives and state of advancement. J Neurol Sci. 2009;286:114–118.
   PubMed Web of Science ®Google Scholar
• Spanier JA, Nashold FE, Mayne CG, et al. Vitamin D and estrogen synergy in Vdr-expressing CD4(+) T cells is essential to induce helios(+)FoxP3(+) T cells and prevent autoimmune demyelinating disease. J Neuroimmunol. 2015;286:48–58.
   PubMed Web of Science ®Google Scholar
• Etemadifar M, Janghorbani M. Efficacy of high-dose vitamin D3 supplementation in vitamin D deficient pregnant women with multiple sclerosis: preliminary findings of a randomized-controlled trial. Iran J Neurol. 2015;14:67–73.
   PubMed Web of Science ®Google Scholar
• Pozzilli C, De Giglio L, Barletta VT, et al. Oral contraceptives combined with interferon beta in multiple sclerosis. Neurol Neuroimmunol Neuroinflamm. 2015;2:e120.
   PubMed Web of Science ®Google Scholar
• Talmage GD, Coppes OJM, Javed A, et al. Natalizumab stabilizes physical, cognitive, MRI, and OCT markers of disease activity: a prospective, non-randomized pilot study. PLoS One. 2017;12:e0173299.
   PubMed Web of Science ®Google Scholar
• Bergsland N, Zivadinov R, Dwyer MG, et al. Localized atrophy of the thalamus and slowed cognitive processing speed in MS patients. Mult Scler. 2016;22:1327–1336.
   PubMed Web of Science ®Google Scholar
• Bermel RA, Bakshi R. The measurement and clinical relevance of brain atrophy in multiple sclerosis. Lancet Neurol. 2006;5:158–170.
   PubMed Web of Science ®Google Scholar
• Koini M, Filippi M, Rocca MA, et al. Correlates of executive functions in multiple sclerosis based on structural and functional MR imaging: insights from a multicenter study. Radiology. 2016;280:869–879.
   PubMed Web of Science ®Google Scholar
• Houtchens MK, Benedict RH, Killiany R, et al. Thalamic atrophy and cognition in multiple sclerosis. Neurology. 2007;69:1213–1223.
   PubMed Web of Science ®Google Scholar
• Motl RW, Zivadinov R, Bergsland N, et al. Thalamus volume and ambulation in multiple sclerosis: a cross-sectional study. Neurodegener Dis Manag. 2016;6:23–29.
   PubMed Web of Science ®Google Scholar
• Ciampi E, Pareto D, Sastre-Garriga J, et al. Grey matter atrophy is associated with disability increase in natalizumab-treated patients. Mult Scler. 2017;23:556–566.
   PubMed Web of Science ®Google Scholar
• Wilting J, Rolfsnes HO, Zimmermann H, et al. Structural correlates for fatigue in early relapsing remitting multiple sclerosis. Eur Radiol. 2016;26:515–523.
   PubMed Web of Science ®Google Scholar
• Klawiter EC, Schmidt RE, Trinkaus K, et al. Radial diffusivity predicts demyelination in ex vivo multiple sclerosis spinal cords. Neuroimage. 2011;55:1454–1460.
   PubMed Web of Science ®Google Scholar
• Song SK, Yoshino J, Le TQ, et al. Demyelination increases radial diffusivity in corpus callosum of mouse brain. Neuroimage. 2005;26:132–140.
   PubMed Web of Science ®Google Scholar
• Budde MD, Xie M, Cross AH, et al. Axial diffusivity is the primary correlate of axonal injury in the experimental autoimmune encephalomyelitis spinal cord: a quantitative pixelwise analysis. J Neurosci. 2009;29:2805–2813.
   PubMed Web of Science ®Google Scholar
• Chen JT, Easley K, Schneider C, et al. Clinically feasible MTR is sensitive to cortical demyelination in MS. Neurology. 2013;80:246–252.
   PubMed Web of Science ®Google Scholar
• Fjaer S, Bo L, Lundervold A, et al. Deep gray matter demyelination detected by magnetization transfer ratio in the cuprizone model. PLoS One. 2013;8:e84162.
   PubMed Web of Science ®Google Scholar
• Schmierer K, Scaravilli F, Altmann DR, et al. Magnetization transfer ratio and myelin in postmortem multiple sclerosis brain. Ann Neurol. 2004;56:407–415.
   PubMed Web of Science ®Google Scholar
• Filippi M, Rocca MA. MR imaging of multiple sclerosis. Radiology. 2011;259:659–681.
   PubMed Web of Science ®Google Scholar
• Ontaneda D, Fox RJ. Imaging as an outcome measure in multiple sclerosis. Neurotherapeutics. 2017;14:24–34.
   PubMed Web of Science ®Google Scholar
• Laule C, Vavasour IM, Kolind SH, et al. Magnetic resonance imaging of myelin. Neurotherapeutics. 2007;4:460–484.
   PubMed Web of Science ®Google Scholar
• Fox RJ, Cronin T, Lin J, et al. Measuring myelin repair and axonal loss with diffusion tensor imaging. AJNR Am J Neuroradiol. 2011;32:85–91.
   PubMed Web of Science ®Google Scholar